研究单位:[1]Peking University Insititute of Hematology, Peking University People's Hospital[2]Beijing Hospital[3]Navy General Hospital, Beijing[4]Beijing Tongren Hospital[5]Peking University Insititute of Hematology, Peking University People's Hospital,Beijing,China,100044[6]Navy General Hospital,Beijing,China,100048[7]Beijing Hospital,Beijing,China,100730
Randomized, open-label, multicentre study to assess the efficacy and safety of the combination of low-dose rituximab and ATRA in patients with steroid-resistant/relapsed ITP.